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IVT-AFL 2q8 versus ranibizumab 0.5q4, and an indirect comparison of IVT-AFL 
2q8 with ranibizumab 0.5PRN data. A de novo health economic model combined 
these clinical inputs with Dutch-specific costs associated with treatment, moni-
toring, and indirect caregiving, and utility inputs relevant to a Dutch popula-
tion. Total quality-adjusted life-years (QALYs) and costs were calculated over a 
15-year horizon. Uncertainty around the outcomes was tested through sensitivity 
analyses. Results: Compared with ranibizumab 0.5q4, a 2-year treatment IVT-
AFL is associated with a significantly lower cost of € 7337 (95% CI: € 7248–€ 7435) 
over a 15-year horizon. There is no significant difference in QALYs (–0.0027 [95% 
CI: –0.0057 to 0.0001]). IVT-AFL 2q8 also has significantly lower total costs than 
ranibizumab 0.5PRN (€ 2450 [95% CI: € 2349–€ 2549]), with a nonsignificant gain of 
0.0007 QALYS (95% CI: –0.0023 to 0.0036). Probabilistic analyses show that, due to 
its lower costs, IVT-AFL 2q8 treatment had an estimated > 99% probability of being 
cost-effective compared with both of the ranibizumab treatment strategies at a 
willingness-to-pay threshold of € 20,000 per QALY, the proposed informal Dutch 
threshold. The univariate analyses did not alter the conclusions. ConClusions: 
The analysis showed that IVT-AFL 2q8 treatment is associated with cost savings 
versus ranibizumab 0.5q4 or 0.5PRN. There is no significant difference in total 
QALYs between the treatments. Due to lower overall costs, IVT-AFL is a cost-
effective treatment option for wAMD patients in the Netherlands.
PSS31
CoSt-Utility AnAlySiS of APremilASt for the treAtment of moderAte 
to Severe PSoriASiS in SPAin
Carrascosa JM1, Vanaclocha F2, Caloto T3, Echave M4, Oyagüez I4, Tencer T5
1Department of Dermatology, Germans Trias i Pujol University Hospital, Barcelona, Spain, 
2Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain, 3Department 
of Health Economics, Celgene Corporation, Madrid, Spain, 4Pharmacoeconomics & Outcomes 
Research Iberia, Madrid, Spain, 5Celgene Corporation, Warren, NJ, USA
objeCtives: A cost-utility model was developed to assess the impact of plac-
ing apremilast, a new oral treatment, before biologics in patients with moderate 
to severe plaque psoriasis who have failed to respond to, have a contraindica-
tion to, or are intolerant to other systemic treatments from a Spain payer per-
spective. Methods: A 20-year Markov model with monthly cycle duration was 
developed. Treatment strategies consisted of apremilast prior to a biologic drug 
sequence compared with a biologic-only sequence. Sequential biologics, based 
on Spanish clinical practice, were adalimumab, ustekinumab, etanercept, and 
infliximab for both strategies. Patients who failed infliximab were assumed to 
receive best supportive care. A ≥ 75% reduction in Psoriasis Area and Severity 
Index was used as the efficacy measure. Drug response rates were derived from 
a meta-analysis. All-cause overall mortality was considered. Resource consump-
tion was estimated by an expert panel; biologic doses were taken from sum-
maries of the product characteristics. According to the NHS perspective, total 
costs included drug acquisition (ex-factory price with mandatory deduction), 
administration (parenteral drugs), and monitoring costs. Unit costs (€ , 2014) were 
obtained from national databases. An annual discount rate of 3% was applied for 
costs and health benefits. Utilities were estimated from PASI response using a 
published regression equation. Sensitivity analyses were performed to test model 
robustness. Results: The administration of apremilast before a sequence of bio-
logic drugs was estimated to provide an additional 0.12 quality-adjusted life-years 
(QALYs): 12.37 QALYs vs. 12.25 QALYs with the biologic-only sequence. In the 
base-case assumptions, the apremilast sequence yielded lower total costs vs. the 
biologic-only sequence (€ 216,490 vs. € 224,359). ConClusions: The administration 
of apremilast before biologic drugs is a cost-saving strategy for the NHS in the 
treatment of patients with moderate to severe plaque psoriasis. This analysis was 
limited in that the model did not consider cost-effectiveness issues.
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objeCtives: To estimate the incremental cost-effectiveness ratio (ICER) of intra-
vitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic 
macular oedema (DMO) in Sweden. Methods: A Markov model was developed 
targeting patients with visual impairment due to DMO in Sweden, based on data 
from the VIVID/VISTA and RESTORE clinical trials. A one-eye model was used in 
base case and patients were followed according to visual acuity in their study eye 
with a time horizon of 15 years. Eight mutually exclusive, exhaustive health states 
were specified and defined in terms of ETDRS letters read. Benefits were measured 
with utility specified as a function of the visual acuity of both eyes in combination. 
The main outcome was incremental cost per additional quality-adjusted life-years 
(QALYs) evaluated from a societal perspective. Univariate and probabilistic sensitiv-
ity analyses (PSA), and scenario analyses were conducted. Results: Intravitreal 
aflibercept was shown to be cost-effective versus intravitreal ranibizumab with 
an ICER of 128,323 (€ 13,821) SEK/QALY gained. The higher total cost for intravitreal 
aflibercept compared to intravitreal ranibizumab predominantly reflected the drug 
and administration costs while intravitreal ranibizumab showed a higher cost for 
monitoring. The incremental cost and QALYs were estimated to 5,227 SEK (€ 563) 
and 0.041, respectively. Univariate sensitivity analyses showed that the ICER was 
sensitive to the number of treatments and the administration costs. PSA showed 
that with a willingness-to-pay threshold of 500,000 SEK/QALY intravitreal aflibercept 
was estimated to have 68% chance of being cost-effective compared with intravitreal 
ranibizumab. In a number of scenarios, intravitreal aflibercept was estimated to 
be cost-effective against intravitreal ranibizumab including: four different sets of 
utilities; adjustment of treatment duration and discount rates; different time hori-
zons and with and without indirect costs. ConClusions: In Sweden, intravitreal 
aflibercept may be a cost-effective option versus intravitreal ranibizumab for the 
treatment of DMO using 500 TSEK as threshold.
years. This sequence remained dominant or cost saving in all the deterministic 
sensitivity analyses, changing efficacy data, utility weights, or discount rates. 
Resultswere more sensitive to changes in the time horizon of the analysis. The 
probabilistic sensitivity analysis confirmed that the apremilast sequence was 
dominant or cost saving in a large majority of the simulations. ConClusions: 
This analysis suggests that the use of apremilast for treatment of moderate to 
severe psoriasis may represent a cost-saving option for the Italian NHS without 
any loss in patients’ quality of life.
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objeCtives: Choroidal neovascularization (CNV) is the most common vision-
threatening complication associated with pathologic myopia (PM), a progressive 
condition characterized by axial elongation and degenerative changes in the 
posterior segment of the eye. This study aimed to evaluate the cost effective-
ness of ranibizumab compared with verteporfin photodynamic therapy (vPDT) 
in patients with visual impairment due to myopic CNV in the Portuguese set-
ting. Methods: A Markov model was developed with health states defined by 
best-corrected visual acuity and a 3-month cycle length. The study has taken 
under National Health Service perspective and included societal perspective in 
an alternative scenario, considering a lifetime time horizon. The study was based 
on 2013 prices considering future costs and health outcomes to be discounted at 
5.0% per annum. The baseline characteristics considered were retrieved from the 
phase III RADIANCE study (Ranibizumab and vPDT Evaluation in Myopic CNV), and 
VIP study (Verteporfin in Photodynamic Therapy). Extensive sensitivity analyses 
tested the robustness of the model. Results: From NHS perspective, the lifetime 
cost of treating myopic CNV with ranibizumab was € 8,241.73 whereas vPDT was 
associated with a total cost of € 10,732.81. In the alternative scenario, from societal 
perspective those costs amount to € 8,815.22 and € 11.333,83, for ranibizumab and 
vPDT, respectively. Ranibizumab treatment produced higher cumulative quality-
adjusted life-years (QALYs; 8.95) than vPDT (8.70). Ranibizumab treatment was 
therefore dominant in both scenarios, with greater health gains and lower overall 
costs than vPDT. In the probabilistic sensitivity analysis, ranibizumab had a 100% 
probability of being cost effective compared with vPDT, at an informal willingness-
to-pay threshold of € 30.000/QALY. ConClusions: This cost effectiveness study 
indicates that the therapy with ranibizumab is dominant over vPDT for the treat-
ment of visual impairment due to CNV secondary to pathologic myopia from both 
NHS and society perspectives.
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objeCtives: The optimal treatment strategy for moderate to severe plaque 
psoriasis remains to be determined. In its absence, switching between various 
treatment options, especially biologics, is a common practice among prescribers. 
We assessed the cost-effectiveness of placing a new oral treatment, apremilast, 
before biologics for moderate to severe plaque psoriasis from a Scottish payer 
perspective. Methods: A 10-year Markov transition cohort model was developed 
comparing alternative treatment sequences: (1) apremilast followed by etanercept 
followed by adalimumab and (2) adalimumab followed by etanercept. Patients 
failing etanercept received best supportive care (BSC) as last line of treatment 
in both sequences. Response was defined as a 75% reduction in Psoriasis Area 
and Severity Index (PASI) score at the end of the trial periods (12-16 weeks). Non-
responders moved to the next treatment line. A 20% all-cause annual dropout 
rate was assumed for each treatment. Efficacy inputs were obtained from a net-
work meta-analysis. Unit costs were sourced from the British National Formulary, 
NHS reference costs, and other published sources. A 3.5% annual discount rate 
was applied to costs and quality-adjusted life-years (QALYs). Utility gains by PASI 
response were obtained from a published regression equation. Results: Placing 
apremilast before biologics was a dominant strategy. The apremilast arm pro-
vided an additional 0.74 years in which patients achieved a 75% reduction from 
baseline PASI score and an additional 0.09 QALYs (7.00 vs. 6.91 QALYs). Total time 
spent on biologics and in BSC was reduced by 0.47 and 1.01 years, respectively. 
Total costs were reduced by £3,206. Sensitivity analyses showed robust results. 
Similar Resultswere obtained when combinations of other biologics, including 
ustekinumab, were used in a 2- or 3-drug sequence. ConClusions: Placing 
apremilast before biologics is a dominant strategy in moderate to severe plaque 
psoriasis treatment.
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objeCtives: This study investigates the cost-effectiveness of 2 mg IVT-AFL every 
8 weeks (2q8), after 3 monthly starting doses, compared with 0.5 mg ranibizumab 
every 4 weeks (0.5q4) and a strategy of a 3-month 0.5q4 starting dose ranibizumab 
followed by 0.5 mg every 4–12 weeks as needed (0.5PRN) with 2-year treatment 
durations in Dutch wAMD patients. Methods: A cost-effectiveness analysis was 
conducted, utilising clinical data from head-to-head randomised clinical trials of 
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infliximab, ustekinumab) was explored. From the annual eligible psoriasis popula-
tion (N= 16,322), 5% (n= 816), 11% (n= 1,795), and 18% (n= 2,938) were assumed to 
be treated with apremilast for the first, second, and third years. A local expert 
panel provided detailed resource consumption information. Total cost included 
drug acquisition based on drug doses from summaries of product characteristics 
(ex-factory price with mandatory deduction), administration (parenteral drugs), 
and monitoring costs. Unitary costs (€ , 2014) were obtained from national data-
bases. Results: Total budget for the scenario without apremilast was € 193,677,634, 
€ 192,945,426, and € 192,077,291 in the first, second, and third years. Pharmaceutical 
cost represented 95% of the total. Following apremilast introduction, total budgets 
were reduced by € 2,194,450, € 4,827,791, and € 7,900,021 in the first, second, and 
third years. Incremental drug costs/patient comparing the scenario with apremi-
last vs. without apremilast were € −134.44 (−1.13%), € −295.78 (−2.50%), and € −484.00 
(−4.11%) in the first, second, and third years. ConClusions: Apremilast treatment 
for psoriasis patients who have failed to respond to, have a contraindication to, or 
are intolerant of other systemic therapy would imply a budget impact decrease on 
overall healthcare expenditure for NHS. This analysis was limited in that the model 
did not consider cost-effectiveness issues.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of moderate to severe chronic plaque 
psoriasis for adult patients who have failed to respond to, have a contraindication 
to, or are intolerant to other systemic therapy in Italy. Methods: A budget impact 
model was adapted to the Italian setting using local epidemiological and cost data 
to assess the financial impact of the introduction of apremilast to the market for the 
Italian National Health Service (NHS). The analysis was conducted over a 3-year time 
horizon considering year 2016 as baseline. We used real data of market consumption 
(IMS 2014 data), reflecting the budget holder’s perspective and a real-world 2015 study 
concerning the healthcare resource consumption related to each treatment included 
in the analysis (apremilast, etanercept, infliximab, adalimumab, or ustekinumab). 
Market penetration of apremilast was based on manufacturer’s assumptions. Unit 
costs were taken from Italian standard sources. Frequency of screening and monitor-
ing tests was obtained from real-world data (database analysis). Results: A total of 
≈11,500 patients were considered as the model population at the first year, with an 
assumed 5%-7% annual growth rate. The introduction of apremilast over the next 3 
years, assuming a market share of 1%-5%, 10%-15%, and 15%-20%, for the first, second, 
and third year, respectively, would lead to cost savings varying from a minimum of 
€ 10,150,000 to a maximum of € 15,480,000 for the 3 years. In particular, drug savings 
account for 91% each year, whereas monitoring savings account for 3% and admin-
istration savings account for 6%. ConClusions: This analysis suggests that the use 
of apremilast for the treatment of moderate to severe psoriasis may represent a cost-
saving option for the Italian NHS over the first 3 years of utilisation.
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objeCtives: Routine clinical practice in UK patients with severe dry eye disease 
is a combination of artificial tears (AT) and ocular lubricant ointments. This study 
aims to assess the cost-effectiveness to the UK NHS of the addition of Ikervis® 
(Ciclosporin A; CsA) to routine practice for patients who have not adequately 
responded to therapy. Methods: Using a Markov framework, future health effects 
and costs were modeled. Eligible patients receive six months therapy with Ikervis® 
plus AT and ocular lubricants or AT and ocular lubricants without CsA. Upon com-
pletion, those who respond sufficiently remain on CsA treatment for the dura-
tion of the response, achieving a higher quality of life (HRQoL) and lower AT use. 
Incremental cost effectiveness ratios (ICER) were expressed in GBP (£) per QALY 
gained with costs and health effects discounted at 3.5% over a lifetime time hori-
zon. Deterministic and probabilistic sensitivity analyses were employed to assess 
the effect of uncertainty on the model. Scenario analyses including less stringent 
improvement criteria, alternative approaches to deriving response stratified utility 
values and a shorter initial trial period were performed. Results: Compared with 
AT alone, Ikervis® Resultsin a lifetime cost to the UK NHS of £934 per patient, but 
offers an additional 0.03 QALYs. The ICER is £35,805/QALY gained. At a commonly 
accepted cost-effectiveness threshold of £30,000 per QALY, Ikervis® is cost-effective 
in 32.4% of simulations. Tornado analysis showed the model is most sensitive to 
the incremental benefit on patient’s long-term HRQoL associated with respond-
ing to therapy compared with non-response. ConClusions: The modelling study 
showed that from an NHS perspective, health gains can be achieved at a low cost. 
The Ikervis® ICERs are well below the NICE’s commonly accepted cost-effectiveness 
threshold of £30,000/QALY gained, indicating that Ikervis® in the target patient 
population could represent a cost-effective intervention in the UK.
PSS38
drUg UtiliSAtion And heAlthCAre reSoUrCeS USe in PAtientS with 
PSoriAtiC ArthritiS And PSoriASiS
Degli Esposti L, Sangiorgi D, Buda S, Crovato E
CliCon S.r.l., Ravenna, Italy
objeCtives: This study aimed to assess therapeutic strategies in clinical practice for 
patients with psoriatic arthritis (PsA) or psoriasis and calculate related healthcare 
resources consumption. Methods: An observational retrospective cohort analy-
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objeCtives: To evaluate the cost-effectiveness of intravitreal aflibercept (IVT-AFL) 
versus intravitreal ranibizumab for the management of neovascular age-related 
macular degeneration (nAMD) in Greece. Methods: A Markov “better-eye-treated” 
model consisting of 6 health states (5 states related to vision impairment, and 
death) was adapted in the Greek healthcare setting to compare monthly (2q4) and 
bimonthly (2q8; following 3 monthly loading doses) treatment with 2 mg IVT-AFL 
with 0.5 mg ranibizumab either on a monthly basis (0.5q4) or as needed (PRN). The 
time horizon of analysis was 20 years. All patients were assumed to discontinue 
treatment at the end of the second year. Clinical inputs and utility values were 
extracted from the literature. The analysis was conducted from a payer perspec-
tive and, as such, only costs reimbursed by the payer were considered (in 2014 
euros). Costs and outcomes were discounted by 3.5% per year. The primary out-
comes were costs, quality-adjusted life years (QALYs), and the incremental cost-
effectiveness ratio per QALY gained. Probabilistic sensitivity analysis (PSA) was 
conducted. Results: IVT-AFL 2q8 was the least expensive regimen (€ 21,930) while 
ranibizumab 0.5q4 was the most expensive (€ 26,203). For all regimens, the total 
cost was driven mainly by the direct nonmedical costs, followed by drug acquisi-
tion costs. In terms of QALYs, IVT-AFL 2q4 was the most efficacious (4.057), while 
IVT-AFL 2q8 was more efficacious (4.049) than ranibizumab PRN (4.025) but less 
efficacious than ranibizumab 0.5q4 (4.052). Although IVT-AFL 2q4 was more effica-
cious than IVT-AFL 2q8, the former cost approximately € 350,000 per QALY gained 
compared with the latter. Both ranibizumab regimens were deemed inferior. PSA 
revealed that at all willingness-to-pay thresholds up to € 335,000, IVT-AFL 2q8 had 
the highest probability of being cost-effective compared with the other treatment 
strategies. ConClusions: Bi-monthly treatment with IVT-AFL may be the most 
cost-effective option for the treatment of nAMD in Greece.
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objeCtives: The objective of this analysis is to evaluate the cost-effectiveness 
of Conbercept versus Ranibizumab in treating neovascular age-related macular 
degeneration (AMD), the third leading cause of irreversible blindness worldwide, 
from China perspective. Methods: A Markov model, based on best corrected visual 
acuity (BCVA) letters, was developed to simulate the progression of neovascular 
AMD among Chinese and to predict the outcomes of Conbercept and Ranibizumab 
treatment over 1 year. The initial distribution of visual acuity was estimated 
from MARINA trial. Disease progression was characterized by a series of annual 
transitions between 5 health states referred to as 90, 75, 60, 45, 30 BCVA letters. 
A patient’s visual acuity was assumed to either increase by 15 letters, remain the 
same, decrease by 15 letters or decrease by 30 letters each year. The transition prob-
abilities of Ranibizumab were estimated based on the reported data of EXTEND II 
trial. The Transition probabilities of Conbercept were extracted from AURORA trial. 
Utility values were taken from a cross-sectional study. Cost data, including drug 
cost, administering cost and caregivers cost in different health states, were derived 
from literatures and direct physician survey. One-way sensitivity analysis was con-
ducted on selected key parameters. Results: One-year total cost was 79,189.94 and 
141,291.23 RMB for Conbercept and Ranibizumab respectively; QALY of Conbercept 
and Ranibizumab was 0.725 and 0.715 respectively. The result suggests a dominant 
ICER of -6,210,129 RMB/QALY, which indicates that Conbercept, when compared with 
Ranibizumab in Chinese AMD population, has demonstrated better efficacy and 
overall lower costs. The one-way sensitivity analysis of key parameters (unit price 
and annual injection times) didn’t change the conclusion, indicating the robust-
ness of the results. ConClusions: Compared with Ranibizumab, Conbercept is a 
cost-effective alternative for the treatment of age-related macular degeneration in 
Chinese people. Conbercept provides better efficacy with overall lower cost.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of adult patients with moderate to 
severe psoriasis who have failed to respond to, have a contraindication to, or are 
intolerant of other systemic therapy in Spain. Methods: A budget impact model 
was developed to estimate healthcare costs for adults with moderate to severe 
psoriasis over 3 years from the NHS perspective. Target population was defined 
based on epidemiological criteria; psoriasis prevalence (2.30%) and proportion of 
patients on biologic treatment (18%) were applied to national adult population sta-
tistics. Addition of apremilast to the therapeutic arsenal (adalimumab, etanercept, 
